<SEC-DOCUMENT>0000950170-24-097206.txt : 20240814
<SEC-HEADER>0000950170-24-097206.hdr.sgml : 20240814
<ACCEPTANCE-DATETIME>20240814171506
ACCESSION NUMBER:		0000950170-24-097206
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240813
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240814
DATE AS OF CHANGE:		20240814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36620
		FILM NUMBER:		241209526

	BUSINESS ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eldn-20240814.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-14T17:09:42.8906+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:eldn="http://www.eledon.com/20240814" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_a4983550-b67e-4bac-85d5-12adaa4f46ff" name="dei:EntityCentralIndexKey" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d">0001404281</ix:nonNumeric><ix:nonNumeric id="F_90bdb95c-5299-4161-948f-d1ffa65a8ec5" name="dei:AmendmentFlag" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eldn-20240814.xsd"/></ix:references><ix:resources><xbrli:context id="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-14</xbrli:startDate><xbrli:endDate>2024-08-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37458b23-758f-4753-a0b4-5d48ee27a15b" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_10744358-d413-40fb-8f1a-dde98dc0a6b9" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">August 13, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9169dc92-f938-446c-bf2b-843e4de299b0" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Eledon Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:18%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_db1ee3f3-bdae-4f68-86f1-0b0c5625b528" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6ed03ad5-2b18-40df-a3d1-3928181d5e3a" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-36620</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_10dbccc5-e383-4235-b64e-ee320c6818ca" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">20-1000967</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f5c4ef23-e3a1-4ea7-b0bd-beb89c0e6c26" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">19800 MacArthur Blvd.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9dd55480-1f6c-48d5-adb5-2cae746c3651" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 250</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_29ffec0a-7fa3-44e0-afeb-75857e9a8ce6" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Irvine</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_ecf786e7-f866-4a79-9d4b-5d7ee05a9110" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_37a51fc3-487f-4c91-90df-af7830b30548" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92612</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_b301fa40-38fc-43d1-9a58-b2a0654e9039" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">949</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_ad4d1076-906b-4cba-ab8a-65d0a36e8534" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">238-8090</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a1418c8-00ee-40f2-b983-5cbe40d2a870" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2096b6c4-d93c-4a04-9eba-24b27ab12d8b" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_095ee66e-975d-48a5-bd3b-ace735a40efb" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c858b44a-99ef-4b5e-a790-32b1c0558ea2" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a75f4ffc-0c5e-461e-b676-7487f4b3ce05" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1beb1e76-73c1-477f-b6c7-bb45967995ed" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ELDN</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0e41dfd0-8959-4420-a36e-d3546539bcac" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_aba5fff0-6265-452c-9d24-7e831ed962f1" contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2024, Eledon Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release regarding its quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change of Accounting for Warrant Derivative Liabilities</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">On May 20, 2024, the partners and professional staff of KMJ Corbin &amp; Company LLP (&#8220;KMJ&#8221;), which was engaged as the Company's independent registered public accounting firm joined Crowe LLP (&#8220;Crowe&#8221;). In connection with this transition, the Audit Committee of the Board of Directors of the Company (the &#8220;Audit Committee&#8221;) dismissed KMJ as the Company's independent registered public accounting firm on July 10, 2024. On July 10, 2024, following the dismissal of KMJ, the Company, through and with the approval of its Audit Committee, appointed Crowe as its independent registered public accounting firm. In the course of preparing the Company&#8217;s financial statements as of and for the three and six months ended June 30, 2024, the Company, in consultation with Crowe, determined that a correction was necessary with respect to the Company&#8217;s reporting and recording of the fair value of (i) certain common stock warrants (the &#8220;Common Warrants&#8221;) issued by the Company in May 2023 pursuant to a Securities Purchase Agreement dated as of April 28, 2023 by and among the Company and certain institutional and accredited investors (the &#8220;Securities Purchase Agreement&#8221;), and (ii) the potential issuance of pre-funded warrants in lieu of additional shares of common stock, $0.001 par value per share (the &#8220;Subsequent Closing Warrants&#8221;), issuable by the Company in a second closing and a third closing of the Securities Purchase Agreement contingent upon the satisfaction or waiver of certain specified conditions set forth therein.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has historically reported the Common Warrants and Subsequent Closing Warrants as equity instruments, because (i) of the respective holders&#8217; ability to settle the Common Warrants and Subsequent Closing Warrants by issuance of a fixed number of shares of common stock or Pre-funded Warrants and (ii) the Common Warrants and Subsequent Closing Warrants contain a fixed exercise price and contain no cash settlement obligation. However, in July 2024, management of the Company, in consultation with Crowe, concluded that the Common Warrants and the Subsequent Closing Warrants do not meet the conditions to be classified as equity instruments under Accounting Standards Codification (&#8220;ASC&#8221;) 815-40, &#8220;Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity,&#8221; and must instead be recorded as liabilities on the Company&#8217;s balance sheet at their fair value and remeasured at fair value for each subsequent reporting period.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management has discussed these non-cash corrections with the Audit Committee. On August 13, 2024, management and the Audit Committee together concluded that the Company&#8217;s previously issued (i) audited financial statements as of and for (i) the fiscal year ended December 31, 2023 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 28, 2024, as amended on April 26, 2024 and (ii) the Company&#8217;s previously issued unaudited condensed financial statements as of and for (a) the three months ended March 31, 2024 included in the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024, (b) the three and nine months ended September 30, 2023 included in the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023 and (c) the three and six months ended June 30, 2023 included in the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023 (together, the &#8220;Impacted Reports&#8221;) were each materially misstated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company is currently not in a position to provide a reasonable estimate of the anticipated changes in its results of operations for the periods impacted, for any Impacted Reports. However, the errors are not expected to result in any impact on its cash and short-term investment position, cash runway, or operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">These identified non-cash errors will result in a restatement of the Additional paid-in capital and Total liabilities and Other income (expense) line items in the Company's financial statement captions. The majority of the financial</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">restatement impact is expected to be reversed in the second half of 2024, as the second and third closings pursuant to the Securities Purchase Agreement are expected to be settled.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As a result, management and the Audit Committee determined on August 13, 2024 that the Impacted Reports require restatement and should no longer be relied upon. In addition, any previously issued or filed earnings releases, investor presentations or other communications describing the Company&#8217;s financial statements as and for the year ended December 31, 2023 or as of and for the three months ended March 31, 2024 should no longer be relied on.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In connection with the restatement described above, the Company identified a material weakness in its internal control over financial reporting related to its accounting for equity instruments. Due to the material weakness, the Company has concluded, and will disclose within the Impacted Reports, that its internal control over financial reporting was not effective as of December 31, 2023 and that its disclosure controls and procedures were not effective as of June 30, 2023, September 31, 2023, December 31, 2023 and March 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has discussed the matters disclosed in this Current Report on Form 8-K with its independent registered public accounting firm, Crowe, and its predecessor registered public accounting firm, KMJ, and intends to file amendments to each of the Impacted Reports reflecting the reclassification of the Common Warrants and Subsequent Closing Warrants and the restatement of the Company&#8217;s financial statements included in the previously issued Impacted Reports as described above. The restatement of the financial statements discussed above does not impact the Company&#8217;s financial results for the three months ended June 30, 2024 as reported in the Company&#8217;s earnings release furnished with the SEC in Item 2.02 of this Current Report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:89%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eldn-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release Issued on August 14, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;"/>
    <td style="width:44%;"/>
    <td style="width:4%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Eledon Pharmaceuticals, Inc.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 14, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David-Alexandre C. Gros, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: David Alexandre C. Gros, M.D.<br/>Title: Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>eldn-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="margin-left:360pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><img src="img20068692_0.jpg" alt="img20068692_0.jpg" style="width:166px;height:42px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;font-style:italic;min-width:fit-content;">Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;font-style:italic;min-width:fit-content;">80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;font-style:italic;min-width:fit-content;">Completed an oversubscribed $50 million private placement; Company expects sufficient liquidity through December 2025</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">IRVINE, Calif., August 14, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (&#x201c;Eledon&#x201d;) (Nasdaq: ELDN) today reported recent business highlights for its second quarter 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#x201c;We have entered the second half of the year with a strong balance sheet following our oversubscribed $50 million private placement and we are highly encouraged by the progress and reception from the transplant community for our Phase 2 BESTOW trial, which remains on track to complete enrollment by the end of this year,&#x201d; said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. &#x201c;Looking at this progress and the data we presented in June, we continue to believe that tegoprubart has the potential to displace calcineurin inhibitors, the current standard of care, as a first-line immunosuppression agent for patients undergoing kidney transplant.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Second Quarter 2024 and Recent Corporate Developments</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Enrolled the 80th participant in July 2024 in the ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of organ rejection in kidney transplantation.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Presented updated data at the American Transplant Congress (ATC) in June 2024 from the ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Updated data from 13 participants demonstrated that tegoprubart was generally safe and well tolerated, with an overall mean estimated glomerular filtration rate (eGFR) of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m2. Two participants completed over 12 months on therapy post-transplant, and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one-year post-transplant. </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="margin-left:360pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Completed an oversubscribed private placement financing for total gross proceeds of $50.0 million, before deducting any offering related expenses. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Anticipated Upcoming Milestones</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">End of 2024: Complete enrollment in the Phase 2 BESTOW trial of tegoprubart in kidney transplantation.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Mid-2025: Report updated interim clinical data from the ongoing Phase 1b and long-term safety and efficacy extension studies of tegoprubart in kidney transplantation.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Financial Results</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">In the course of preparing the Company&#x2019;s financial statements as of and for the three and six months ended June 30, 2024, the Company, in consultation with Crowe LLP, the Company&#x2019;s independent registered public accounting firm, determined that a reclassification was necessary with respect to the Company&#x2019;s reporting and recording of the fair value of certain common stock warrants and pre-funded warrants associated with the Company&#x2019;s Securities Purchase Agreement dated as of April 28, 2023 (and the potential second and third closings thereof), resulting in a reclassification of these warrants as liabilities on the Company&#x2019;s balance sheet, on a mark-to-market basis.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">The Company expects to restate its audited consolidated financial statements that appeared in its Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 28, 2024, as amended on April 26, 2024, and its unaudited condensed consolidated financial statements that appeared in the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024 (together, the &#x201c;Impacted Reports&#x201d;). As previously disclosed on the Company&#x2019;s Form 12b-25 Notification of Late Filing filed with the SEC today, the Company also expects to delay the filing of its Form 10-Q for the three and six months ended June 30, 2024 in light of the time and resources needed to prepare a complete and accurate Form 10-Q in light of the restatement process . See also the Company&#x2019;s Current Report on Form 8-K filed today for additional information.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">This accounting reclassification is non-cash and is not expected to have an economic impact on the Company&#x2019;s operations or on the Company&#x2019;s cash, cash equivalents and short-term investments, or cash runway.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Eledon ended the second quarter with approximately $83.6 million in cash and cash equivalents, which includes the $50.0 million received in the private placement financing transaction during the second quarter.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="margin-left:360pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">About Eledon Pharmaceuticals and tegoprubart</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company&#x2019;s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand (CD40L), a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in allogeneic kidney transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company&#x2019;s website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">www.eledon.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Follow Eledon Pharmaceuticals on social media: </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">; </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Twitter</font></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company&#x2019;s future expectations, plans and prospects, including statements about enrollment in our clinical trials, the development and future success of product candidates, the company&#x2019;s capital resources and ability to finance operations through December 2025, our filing of amendments to the Impacted Reports and our Form 10-Q for the three and six months ended June 30, 2024, as well as other statements containing the words &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;estimates,&#x201d; &#x201c;intends,&#x201d; &#x201c;predicts,&#x201d; &#x201c;projects,&#x201d; &#x201c;targets,&#x201d; &#x201c;looks forward,&#x201d; &#x201c;could,&#x201d; &#x201c;may,&#x201d; and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the completion of our financial closing procedures; final adjustments; completion of the review by our independent registered public accounting firm; the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sites, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company&#x2019;s capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company&#x2019;s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Qs, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">www.sec.gov</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="margin-left:360pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Investor Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Stephen Jasper<br>Gilmartin Group<br>(858) 525 2047<br></font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">stephen@gilmartinir.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Media Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Jenna Urban<br>Berry &amp; Company Public Relations<br>(212) 253 8881<br></font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">jurban@berrypr.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',serif;min-width:fit-content;">Source: Eledon Pharmaceuticals</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img20068692_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img20068692_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A 7\# 2(  A$! Q$!_\0
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MI_U?^RO^UZGM]>G.>#K^YC\40 32%;EB)@6/S\$Y/J<\UA1VL\T$T\<3-%
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MZE6*W@C:661C@(JC))]@!7QAX_\ '.H>._$<M_<R,MG$S)96W00Q9XXR?F.
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MC8+!I5#+]"NX$=QFOG[X+:(-:^*&E^9!YL%ENO)!N*[=@^1N/20Q\?GQ7O\
M\;+4W7PFUG;$TCQ>3*H5<D8E3<?H%+$^U>!?!/7!HGQ0TX22K%!?J]E(64G.
M\90#'0F18QGWH ^O:*** (+RSM]0L;BRNXQ+;7$;12QGHR,,$<>H)KX5UC3I
M=$UV_P!,DD5Y;&YDMVD3(!9&*DC\17W;//#:V\MQ<2QPP1(7DDD8*J*!DDD\
M  <YKX4UW4_[:\0ZEJOE>3]MNI;GR]V[9O<MC/?&>M 'W#HFIKK6@Z=JJ1F)
M+VUBN5C8Y*AU#8)]LU\7>._^2A^)?^PK=?\ HUJ^SO#^F-HOAO2]*>42M96D
M5L9 ,!RB!<X[9Q7QCX[_ .2A^)?^PK=?^C6H ^N_A]!#;?#GPVD$4<2'3+=R
MJ*%!9HPS'CN6))/<DFNDKG_ G_)//#7_ &"K7_T4M=!0!P/QK7=\(M= ](#^
M4\9KX^K[#^,__))->_W8?_1R5\>4 ?;G_";Z-_:?V+S7QOV?:,#RL_7.<9XS
MC'?IS71UY#XE\-3Z#=9&Z6RD/[J7T_V6]_Y_F!H^&/&4FF^79:@S268^59.K
M1#^J^W;MZ5Z=7 QE352@[_U_6A\YA\YJ4Z\J.-7*[[]O^!YFOXN\(?:R^I:9
M'_I'WIH%'^L_VE_VO4=_KUSO!&D:M;:[]IDMIK:W6,K+YT97>#T R/4 \>GO
MSZ+'(DL:R1NKHX#*RG((/0@TZL%C*BI.D]3NEE%"6)6)B[/>RV;_ *W[GGOQ
M)_X^=/\ ]Q_YBI?AK_S%/^V7_L]1?$G_ (^=/_W'_F*E^&O_ #%/^V7_ +/7
M8_\ D7_UW/)C_P CS^OY#/\ B+_R,%O_ ->J_P#H;UO_  Z_Y%^X_P"OIO\
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MG!KW[2M*L=#TNWTS3+:.VL[=-D42=%'\R2<DD\DDDY)H N5\0>._^2A^)?\
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M4UNU@U61O/2VCNXA)';1>:V55&RN2ZLV_ ;YL9P*]BKS_P""7_)(="_[>/\
MTHDH KZ]IUAX$\5^&M8T*VBL+?4]032+^RM(Q''<B56\IRH^4&-@3D#)#$9Q
MP>A\1>&]*U/4H]5\27<<VCV$.Z.QNBJVL<N6W3R9X<[2% ;A?F/5N,;XI_\
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DW110!XW^TQ_Q\^&O]RY_G'7I'P8_Y))H/^Y-_P"CGHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>eldn-20240814.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-14T17:09:43.2413+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.eledon.com/20240814" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:eldn="http://www.eledon.com/20240814" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eldn-20240814.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140548029053456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 13,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eledon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1000967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19800 MacArthur Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-8090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELDN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-E4DYPH]&09;B(S5'WC3B?PT9>H1-N6'$2&%GN5"6&-,W&_T_$8T'D&6A^[
M](2.(2X-PW.D0XMAU]&(B^S"1I_#6(<0Y_$_,5)=8P5+J@X> @\Y1G"=P) :
M;)-6P7@H]+BB[H-5CX$E)+4* Y7L=D[E],H.KEGD7F08YRB#N+*#\%&MA1H#
MV#<YD 27Y*IU5%WI>:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @
MXXD.620>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ XXD.60=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #CB0Y9HJ"0
MV^\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #CB0Y9F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ..)#EE #O5&;@0  #41
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #CB0Y9GZ ;\+$"  #B#   #0              @ &R#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ..)#EF7BKL<P    !,"   +
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4!08     "0 ) #X"   3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="eldn-20240814.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="eldn-20240814.htm">eldn-20240814.htm</File>
    <File>eldn-20240814.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "eldn-20240814.htm": {
   "nsprefix": "eldn",
   "nsuri": "http://www.eledon.com/20240814",
   "dts": {
    "inline": {
     "local": [
      "eldn-20240814.htm"
     ]
    },
    "schema": {
     "local": [
      "eldn-20240814.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20240814.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20240814.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.eledon.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-24-097206-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-097206-xbrl.zip
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MS5 ]H83EY&(H0HRQ<1*GY+C(R0$0%3K_[OENQ&-1\YN:W& UN8G8UII VSG
M=\F[Y1]Z2UXZYE=&TT $G(?W6_;6MT?6"U7<?"/% U,(.[)IP)F@3M3QJ->)
M3&H$1NAV+#=P+6\U1@H4?R8!/JO%M8L"..L@*]-"C@XR/@U9<<$/EP,*,939
M-=:S5JQZ*!)VPZ1X!$C=#"?JD5/=$=RP&7>I%9B 1PP>49A'D]J^Y9F>R5UA
ML]5,]<<X$=!V(.0:I\TPH.N=CF5\[_-F&CP(P]"EPO; C[1LEP8=1U"06\L(
M.S!WX8KF[9+='E<+>J$2T[5/HF50,#^&W^D^P46<H]6[FZK4-31</<NL8U*V
ME7;&0-MIT1>2_%;*..>QBL"I92Y J%/:_-TZ9>U%4>X@&PSB'#.X""I!H@7H
MC3XU?8[/+\C18)AD(R$5*TWK&W*2M>82:Y[(?R>AT'LG8.XX'^P8O!3;]S;:
MM]&^C?9Q:.?-AU4 .7)#1T26#0"9F=01K$L#(X#QB\#S >QV0JNS&H"\S[D4
M>5[][U.<"G.-UM+T/<,@GUFX+XM^*<G/R35_0.STF\^'S[GK.AY ^Z@34L<#
MEY/Q /S.D(FNTPGMCFNN:SZL-<['10E?$\M]M,<Y%BYKDX5K<_76*O34G$#M
MMY83RX\B$1J,=B,&CKTC#,HB$6"2E-L5/O-"L5J]=0!_GLK+[&:=X;1C>0UR
M>(^(K*OQG0>LRXLPZGH=T:61U^E0AW5]ZG,GH"[O"F&XS#?-%:W+5617[O2I
M/),94";\IK'. ^!.:#V-V4N.FCUXI67=V%)W;A-UB]UEKAF%H%:\;D2=T#>I
MKR*^P/NV$=@&&.B5,OE9!ER<_&\\5.'\]7&P;W5,ZRU8N#DAG6K^<=GZ3()^
MBX<L(4>W(BQQ:R(YC:(X%/E:0V O Q"]RH ?* 2"&F%I5&]NKM?;"OVKRCXU
M+??UII].\GU^_,&SS.YN3BY%(H;]+*W7$%3F5%(BQ<@^D%E)5>^)>'I1/QZ
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M=\)RSOXBOR19P!+RF<DOHEA_LLK]9V$^CE^_3E3F..48@1$D&)%0K<%"-[\
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M5/:>?/ITAL$2I?N@T$3EZ56K&]0;Z17#S1SP)[96??D3YM]S,10J76PZZ22
M"6XZ1E$,2O[/3,6'#L"=$U/-JB=UPRT0!'3=TTJC*XNAS-+$5=.CUJ*DCF8L
M"B%JQ?]S!@ %?QPJ$)_)O'Y3#[FI[F<J&<,? /QXXB/T%RGWS)'#,'XK04N8
M8VQT.O-DI['? %NJFH<9U'.WTVP??\BLO.JK^:X(5.V>N-:?(#B;&=H.%LAP
MRT0]!S J+/>HL:CIP=;@J<P5T8&]@0'KGC=PI-KP.G&4\XE*9&I.L/=19;-@
M1#"%"@+$MT3=:Y+/@Y4SA(@5KZ OP";<HD:W Z86!C)0/*=L,H.B4M9L!5T
M%@-!8;*")6 ;APVS/CL0?4D,#A-["?5D&@?7^T587"WLX9/M^!T)A2Q8K'/I
M,U036?@%VE5*+)_%WEBB4G#Y+ 8/1E/L&]<JP+*GP@NLB1'.2@D@ "9H_TH*
MG73'E0'2I-\?RC@AEK>CJX$6<% ,>C$UB^II/0Z\&#@NU#7/&/; \F$(G!(7
M"M!<BUP)6W-@2SLT4358UW8,)%/*+$-5APR#P]>V5C$9C4K%#V,20I^26)2*
ME;AV]9#-P-712*Q)^+OKKQCOT86GNUP&N?BK1((=)%F.,SP[+SNZ9QCKN#LU
M#+%?AF2KOE:$0@TF)\_N8M0Y\X5*'PKCG^4PTU*GMS4QS<,@.C<,S*!4@ZUF
M*1_?*A'6_F_>P'L(8D6<OGE77\6[JOD"(Y%@PD ^T/U.1N,;IVKN:8J_XI@E
M;*B@_%]E7(R42$IU4Q2X]($(&<8W4?>,-[@IE890J0]P&"!"I<Z(QDTCM7-.
M%)AK]Y2> /LWA13=A5L,MJI]Z/ADOC BYYY-!'JJN;$>>&Q?D/),":#NA+@5
M,D1W#51=J$U+720%?Y3E_6KD2M@FFP-;Y%<P']=X-$-<66EM>&"R 0;ITM'#
MS1"\0)>YMD*+AJ;TP9+A\4RYQ0,ABLK^CJ4;YA \2Q7>U)(_ET$J7[(!JB_&
MX>J#C$\.:ZYAV?[%P=@2>:9+'3#!U:L)!->=_U5P%:I7W&4AN,1;Q$.MH_5*
MRMB.GM[ (]6[G=J;QRH&&+?"[@K&<3C:P.K!3'G8Z5SK'+!$<6'>1P)I.H-!
M;EAE;;4'@N4EPALHTGB),$3E;>63*9@8?+TR\+VY9 ]07&/R-G@?=1G T[!4
MZ!C(#"*6@F>L)&J"L/(),)T!H@K]SMPD-R5=M3C, OPBN])+T_-%:JK#PXEO
M7J$H5(NLU&CE :!TNU)#$0P5RN'=>A4>/038J/2;;5;P*:Z[$\]GSOTT+:&.
MF7B::>C-S**!X1N( #LRCN0T#J"? BM'$Q'-$!8"B*A1W72("]Y6F*^CW]Y1
MMO>0KTQKXJ'F$6G^0#*R=PU\/X7K=6\K(CKW$O&?.M8,/;I+QW_>H>/1@28(
MN%AN30[<]C#M:Z3@'4QWZD(,BVIVC0?.[E,Z=I)=ZU;\JA$U&^%L_Y;Z0NOI
M62V8=1O;M=1ISZMBO&-H2*VKZHHG+LL-P$NM2>M=F- ZLBXRR&M4H1@)#W5
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M)![YNQ'2.WD!.":XQHUHZ52AY6Y!:M.2K/]?2(GHRX0"#EF;BHPS\$)"0DS
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MDZ/Z7THYJJ/\38F)G"K!)HC#RB>J.HV)3$84R.C27$DG9CJ?" DJ'6">&$I
ML@A/3Y0B*)<D=D8 SQ;NDSP7/%TL9DI(IX)JP(69"*O(,5X=SGE_!-.Q(^6A
MATFA,@:)C#GI_A(CBLBF:6'(V9%V$35-8;8E(-=H@K52J8TG0(LUHDLH+ZW
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M+3(P,C0P.#$T+FAT;5!+ 0(4 Q0    ( ..)#EE/#$B#?P@  !)A   1
M          "  =@:  !E;&1N+3(P,C0P.#$T+GAS9%!+ 0(4 Q0    ( ..)
M#EEZ)/7JUQ   (%<   /              "  88C  !E;&1N+65X.3E?,2YH
8=&U02P4&      ,  P"[    BC0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>eldn-20240814_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eldn-20240814.xsd" xlink:type="simple"/>
    <context id="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <startDate>2024-08-14</startDate>
            <endDate>2024-08-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_a4983550-b67e-4bac-85d5-12adaa4f46ff">0001404281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_90bdb95c-5299-4161-948f-d1ffa65a8ec5">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_37458b23-758f-4753-a0b4-5d48ee27a15b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_10744358-d413-40fb-8f1a-dde98dc0a6b9">2024-08-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_9169dc92-f938-446c-bf2b-843e4de299b0">Eledon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_db1ee3f3-bdae-4f68-86f1-0b0c5625b528">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_6ed03ad5-2b18-40df-a3d1-3928181d5e3a">001-36620</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_10dbccc5-e383-4235-b64e-ee320c6818ca">20-1000967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_f5c4ef23-e3a1-4ea7-b0bd-beb89c0e6c26">19800 MacArthur Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_9dd55480-1f6c-48d5-adb5-2cae746c3651">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_29ffec0a-7fa3-44e0-afeb-75857e9a8ce6">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_ecf786e7-f866-4a79-9d4b-5d7ee05a9110">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_37a51fc3-487f-4c91-90df-af7830b30548">92612</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_b301fa40-38fc-43d1-9a58-b2a0654e9039">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_ad4d1076-906b-4cba-ab8a-65d0a36e8534">238-8090</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_9a1418c8-00ee-40f2-b983-5cbe40d2a870">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_2096b6c4-d93c-4a04-9eba-24b27ab12d8b">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_095ee66e-975d-48a5-bd3b-ace735a40efb">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_c858b44a-99ef-4b5e-a790-32b1c0558ea2">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_a75f4ffc-0c5e-461e-b676-7487f4b3ce05">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_1beb1e76-73c1-477f-b6c7-bb45967995ed">ELDN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_0e41dfd0-8959-4420-a36e-d3546539bcac">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_7ca3da5f-025d-40c4-8330-32ac1c0ee46d"
      id="F_aba5fff0-6265-452c-9d24-7e831ed962f1">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
